Ashwini M. Londhe

Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease

Jong‐Hyun Park, Yeon Ha Ju, Ji Won Choi et al. · Science Advances · 2019 · 198 citations · Full text

Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model

Siwon Kim, Ambily Nath Indu Viswanath, Jong‐Hyun Park et al. · Neuropharmacology · 2020 · 106 citations

Biochemistry, Reactive Nitrogen Specie, Medicine +10

Investigation of Molecular Details of Keap1-Nrf2 Inhibitors Using Molecular Dynamics and Umbrella Sampling Techniques

Ashwini M. Londhe, Changdev G. Gadhe, Sang Min Lim et al. · Molecules · 2019 · 62 citations · Full text

Drug Target, Nrf2 Binding Site, Molecular Biology +18

Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders

Ahmed Karam Farag, Ahmed Elkamhawy, Ashwini M. Londhe et al. · European Journal of Medicinal Chemistry · 2017 · 33 citations · Full text

Inflammation, Medicinal Chemistry, Anti-inflammatory +10

Discovery of<i>N</i>-(1-(3-fluorobenzoyl)-1<i>H</i>-indol-5-yl)pyrazine-2-carboxamide: a novel, selective, and competitive indole-based lead inhibitor for human monoamine oxidase B

Ahmed Elkamhawy, Sora Paik, Hyeon Jeong Kim et al. · Journal of Enzyme Inhibition and Medicinal Chemistry · 2020 · 29 citations · Full text